← Back to Search

Small Molecule

ATH434 for Multiple System Atrophy

Phase 2
Waitlist Available
Research Sponsored by Alterity Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant has clinical features of parkinsonism.
Participant has evidence of orthostatic hypotension and/or bladder dysfunction.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to week 52
Awards & highlights

Study Summary

This trial tests a potential treatment for Multiple System Atrophy, to check its safety and effectiveness.

Who is the study for?
This trial is for individuals with Multiple System Atrophy (MSA) who show symptoms like parkinsonism, low blood pressure upon standing, bladder issues, and coordination or movement problems. They must have MSA indicators in their biological fluids and MRI scans. People can't join if they can't swallow pills, attend visits, have other major neurological disorders besides MSA, unstable health conditions, or cannot undergo MRI or lumbar puncture.Check my eligibility
What is being tested?
The study is testing the safety and effectiveness of a drug called ATH434 in people diagnosed with Multiple System Atrophy. It aims to see how well this drug works on the condition's symptoms and progression.See study design
What are the potential side effects?
While specific side effects of ATH434 are not provided here, common types of side effects from drugs treating neurological conditions may include nausea, dizziness, headache, fatigue or sleep disturbances.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I show symptoms similar to Parkinson's disease.
Select...
I experience dizziness when standing up or have bladder control issues.
Select...
My tests show MSA markers in my body fluids and on my MRI.
Select...
I have coordination problems or muscle weakness.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to week 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in iron content as measured by brain MRI
Secondary outcome measures
Change in Aggregating alpha-Synuclein Levels
Change in Neurofilament Light Chain Levels
Change in SF-36 Score
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ATH434Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Alterity TherapeuticsLead Sponsor
2 Previous Clinical Trials
92 Total Patients Enrolled
2 Trials studying Multiple System Atrophy
92 Patients Enrolled for Multiple System Atrophy

Media Library

ATH434 (Small Molecule) Clinical Trial Eligibility Overview. Trial Name: NCT05732415 — Phase 2
Multiple System Atrophy Research Study Groups: ATH434
Multiple System Atrophy Clinical Trial 2023: ATH434 Highlights & Side Effects. Trial Name: NCT05732415 — Phase 2
ATH434 (Small Molecule) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05732415 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical trial available to geriatric patients?

"The stipulated age range for participants in this clinical trial is between 30 and 75."

Answered by AI

Has ATH434 been approved by the US Food and Drug Administration?

"Our team rated ATH434's safety a 2 due to the fact that only pre-clinical data exists which supports its security, but there is no evidence demonstrating efficacy."

Answered by AI

Is this clinical examination open to volunteers at the present moment?

"Clinicaltrials.gov lists this trial as no longer recruiting patients, having first posted on March 1st 2023 and last updated February 8th of the same year. Despite that, 196 other studies are currently registering participants at this time."

Answered by AI

Who is eligible to participate in this research study?

"This clinical trial is looking for 15 individuals suffering from multiple system atrophy, aged between 30 and 75. To qualify, participants must display the following signs: parkinsonism symptoms, orthostatic hypotension/bladder dysfunction, neurological indicators such as ataxia or pyramidal signs, and evidence of MSA in biologic fluid or MRI scans."

Answered by AI

Who else is applying?

What site did they apply to?
Vanderbilt University Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Biomarker Study of ATH434 in Participants With MSA
2023. "Biomarker Study of ATH434 in Participants With MSA". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05732415.
All > Multiple System Atrophy
~5 spots leftby Oct 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top